Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Verve Therapeutics
Biotech
Lilly preps gene editor for ph. 2 after strong cholesterol cuts
A one-time infusion of a Verve base editor led to a sustained 62% drop in cholesterol, clearing the bar set by approved PCSK9 inhibitors.
Darren Incorvaia
May 25, 2026 8:45am
Eli Lilly pays $1B upfront to buy gene editing partner Verve
Jun 17, 2025 4:35am
Boy with rare disease 'thriving' after 1st custom gene therapy
May 15, 2025 1:00pm
Verve posts clean PCSK9 editor profile, teeing up Lilly decision
Apr 14, 2025 7:00am
Vertex axes Verve gene editing pact amid shift in R&D priorities
Feb 27, 2025 9:05am
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
Apr 2, 2024 7:00am
